Aging and hypertension: Integrated renal and sympathetic control of blood pressure

NIH RePORTER · NIH · R01 · $412,500 · view on reporter.nih.gov ↗

Abstract

ABSTRACT The prevalence of hypertension, increases with age from 30% of U.S. adults aged 20-44 to >75% of U.S. adults above the age of 65. Less than half of elderly patients with hypertension achieve adequate blood pressure control and older hypertensive patients are significantly less likely to receive a thiazide prescription (first line anti-hypertensive) than younger patients. This suggests contemporary prescribing practices to the elderly are sub-optimal. This application will test the global hypothesis that attenuated mechanosensitive afferent renal nerve sympathoinhibitory reflexes evoke sodium chloride cotransporter-mediated renal sodium retention and age-dependent hypertension. These studies will employ our novel technique of selective afferent renal nerve ablation, a unique in-vivo surgical approach to activate the mechanosensitive afferent renal nerves, and genetic and pharmacological tools in 3, 8 and 16 month old Sprague-Dawley rats (model of normal aging) that exhibit age-dependent hypertension to provide new mechanistic insight into the pathophysiology of age- dependent hypertension. The following Specific Aims will be conducted to test this hypothesis: Specific Aim 1: Impairments in the renal sympathetic nerves contribute to age-dependent hypertension. Specific Aim 2: Attenuation of the mechanoreceptor-activated sympathoinhibitory afferent renal nerve natriuretic reno-renal reflex occurs in age-dependent hypertension. Specific Aim 3: Age-dependent elevations in sympathetic tone increase NCC activity, via a NE-α1-adrenoceptor-gated WNK1-OxSR1 signal transduction pathway, to evoke renal nerve-dependent sodium retention and hypertension. These hypertension focused studies are central to the mission of the NIA, which is to understand the nature of the aging processes and diseases associated with aging to extend healthy years of life. This supplement contains the new NOT-AG-20-008 Specific Aim 4: Age- dependent increases in blood pressure evoke blood brain barrier dysfunction and memory impairment in the Sprague Dawley rat model of normal aging and in the TgF344-AD rat model of Alzheimer's disease. This New Aim will address the novel hypothesis that age-dependent increases in BP evoke BBB dysfunction and cognitive impairment in the SD rat model of normal aging and in the novel rat model of Alzheimer's disease (TgF344-AD). The unique multi-disciplinary nature of our team, which combines expertise in aging, hypertension, neuroscience, will utilize novel rat models of normal aging and AD and cutting edge in vivo electrophysiology technology to comprehensively test our hypothesis. Completion of this New Aim, which will directly address weaknesses in prior research in this area, will drive a new area research in the critical area of vascular cognitive impairment and AD to support future planned R01 submissions.

Key facts

NIH application ID
10131484
Project number
3R01AG062515-02S1
Recipient
BOSTON UNIVERSITY MEDICAL CAMPUS
Principal Investigator
Richard David Wainford
Activity code
R01
Funding institute
NIH
Fiscal year
2020
Award amount
$412,500
Award type
3
Project period
2019-09-30 → 2024-05-31